[LA Times] Prices of new hepatitis C drugs are tough to swallow for insurers

By Chad Terhune and Eryn Brown
March 9, 2014

 

A pair of new drugs to treat hepatitis C offer a cure for millions of Americans afflicted with the disease — but at a potentially staggering cost to taxpayers and health plans.

Until now, therapies for hepatitis C helped only about half of patients and posed numerous side effects, such as flu-like symptoms, anemia or depression. In comparison, clinical trials of Sovaldi and Olysio have shown cure rates of 80% to 90% with far fewer complications.

 

Read More